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Tracheal smooth muscle precontracted with carbachol relaxes upon the addition of 3 &I okadaic acid. Although cytosolic Caz* concentrations 
decrease, myosin light chain remains highly phosphorylated (50%). In smooth muscle treated with carbachol alone or carbachol plus okadaic acid 
3zP is incorporated into a single peptide on myosin light chain which corresponds to the site phosphorylated by myosin light chain kinase. Treatment 
with okadaic acid alone does not result in myosin light chain phosphorylation or tension development. These results suggest hat a cellular mecha- 
nism other than myosin light chain phosphorylation can regulate contractile tension. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
The phosphorylation of the regulatory light chain of 
myosin (MLC) by Ca’+/calmodulin-dependent MLCK 
is a primary step in the initiation of smooth muscle con- 
traction. Phosphorylation of MLC increases the actin- 
activated myosin MgATPase activity and increases 
cross-bridge cycling rates leading to tension develop- 
ment [ 1,2]. Dephosphorylation of MLC by a protein 
phosphatase results in relaxation. While myosin 
phosphorylation/dephosphorylation may be the domi- 
nant regulatory pathway involved in initiating smooth 
muscle contraction, others have proposed Ca2+ activa- 
tion mechanisms involving thin-filament regulatory 
processes [3,4] which may coexist with the thick- 
filament regulatory scheme involving MLC 
phosphorylation. We report here that okadaic acid, a 
potent protein phosphatase inhibitor [5-71, relaxes 
tracheal smooth muscle precontracted with carbachol 
without affecting MLC phosphorylation. These fin- 
dings raise the possibility that a phosphoprotein(s) 
other than phosphorylated MLC might be involved in 
regulation of tension maintenance in smooth muscle. 
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2.1. Tissue preparation 
Strips of smooth muscle (5-10 mg, wet weight) were prepared 
from bovine trachea as previously described [8]. Muscles, stretched 
to optimal length (L,) for tension development, were clamped after 
described treatments with tongs cooled in liquid nitrogen. After “P- 
labeling, strips were quick-frozen by submersion in 
dichlorodifluoromethane chilled in liquid nitrogen. All frozen 
muscles were stored at -60°C prior to biochemical analyses. 
2.2. Cytosolic Cd+ levels 
Cytosolic Ca2+ concentration [Ca2+] was measured 
simultaneously with muscle contraction as repzted previously [7,9] 
with a fluorescent CaZC indicator, fura- [lo]. Muscle strips were 
loaded with 5 PM acetoxymethyl ester of fura- for 3 h in the 
presence of 0.02% Cremophor EL at room temperature (23-25”(Z) 
and then placed in a tissue bath at 37°C. Each muscle strip was il- 
luminated alternately (48 Hz) with 340 and 380 nm light, and emis- 
sion was detected at 500 nm. The amount of the 500 nm fluorescence 
induced by excitation at 340 and 380 nm was measured, and the ratio 
of the fluorescence values (R~/sso) was calculated. The ratio was us- 
ed as an indicator of [Ca2+lEYt with values normalized to 0% in resting 
and 100% in high K+-stimulated muscle, respectively. 
2.3. Myosin light chain phosphorylation 
Frozen muscle strips (weighing approximately 3-5 mg) were placed 
in 10% trichloroacetic acid in acetone partially frozen (slurry), allow- 
ed to warm to room temperature and then homogenized in 200~1 
10% trichloroacetic acid and 10 mM dithiothreitol. After centrifuga- 
tion, the protein pellet was processed for urea/glycerol-PAGE and 
immunoblotting [11,12]. Relative amounts of non-phosphorylated 
and monophosphorylated light chain were quantified from den- 
sitometric scans of immunostained nitrocellulose blots. 
2.4. Two-dimensional phosphopeptide mapping 
Protein samples from “P-1abelled tissues were subjected to SDS- 
PAGE [12]. Following staining with Coomassie blue, gels were sub- 
jected to autoradiography. The band corresponding to the 20 kDa 
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MLC was excised and processed for phosphopeptide mapping as 
previously described [ 121. 
2.5. Drugs and chemicals 
The following drugs and chemicals were used: carbachol, atropine 
(Sigma Chemical Co., St. Louis, MO, USA), acetoxymethyl ester of 
fura-2, EGTA (Dojindo Laboratories, Kumamoto, Japan), and 
Cremophor EL (Nakarai Chemicals, Kyoto, Japan). Okadaic acid 
isolated from Halichondriu okudui (donated by Dr Daisuke Uemura, 
Shizuoka University) was dissolved in 100% ethanol to a 5 mM 
stock. 
3. RESULTS 
Bovine tracheal smooth muscle contracted in the 
presence of 0.1 ,uM carbachol relaxed upon the addi- 
tion of 3 PM okadaic acid (Fig. 1). The relaxation 
response was associated with a decrease in the in- 
tracellular free Ca2+ concentration by 93% (Fig. 1). 
However, the relaxation process was not associated 
with a decrease in MLC phosphorylation (Table I). 
With carbachol alone, the extent of MLC phosphoryla- 
tion was 53%. With the addition of okadaic acid to 
carbachol-treated tissues, MLC phosphorylation re- 
mained elevated. Treatment with okadaic acid alone 
did not result in MLC phosphorylation or tension 
development. Tissues pretreated with okadaic acid con- 
tracted upon the addition of carbachol although the 
response was attenuated compared to treatment with 
carbachol alone. No additional prominent 
phosphoprotein(s) were detected in muscle strips 
precontracted with carbachol and relaxed with okadaic 
acid compared with tissues treated with carbachol alone 
(Fig. 2). Two-dimensional phosphopeptide mapping of 
Table I 
Effect of carbachol and okadaic acid on tension and myosin light 
chain phosphorylation in bovine tracheal smooth muscle strips 
Condition Fractional Myosin light chain 
tensionavb phosphorylationb 
Relaxed 0 6 + 0.8 
0.1 ,uM carbachol 10 min 1.0 53 * 3 
0.1 pM carbachol 25 min 1.0 51 + 3 
0.1 PM carbachol (10 min) + 
3 ,BM OA 15 min 0.09 + 0.04 50 + 3 
3rMOA 15min 0 0 
a Fractional tension is tension normalized to that produced by 
0.1 pM carbachol at 10 mm 
b Values shown are means f SEM, for 8-10 muscle strips 
MLC showed that the same site was phosphorylated in 
tissues treated with carbachol alone or carbachol plus 
okadaic acid (Fig. 2). The primary [32P]phosphopep- 
tide corresponded to MLC monophosphorylated at 
serine 19 by MLCK [8,12]. 
4. DISCUSSION 
It has been generally accepted that the phosphoryla- 
tion of MLC by Ca’+/calmodulin-dependent MLCK is 
both obligatory and sufficient for the biochemical ac- 
tivation of smooth muscle contraction [ 1,2,13]. Recent 
physiological observations suggest that other 
regulatory mechanisms may modify the Ca2+ sensitivity 
of contractile tension in smooth muscle [14-161. Since 
Fig. 1. Effect of okadaic acid (OA) on [Ca”] FYI and tension in bovine tracheal smooth muscle. Muscles were first contracted in 72.7 mM KC1 
(made by replacing NaCl with KCl) and then with 0.1 PM carbachol (Carb). Carbachol remained thereafter. Atropine (Atr) at 1 PM final 
concentration was added as indicated after treatment with 3 pM okadaic acid. 
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Fig. 2. (A) Autoradiogram of SDS-polyacrylamide gradient gel (3-20%) of homogenates from “P-labeled bovine tracheal smooth muscle (lane 
1, purified [“PJMLC; lane 2, 10 min CCh; lane 3, 25 min CCh; lanes 4 and 5, 10 min CCh + 15 mitt OA; lanes 6 and 7, 15 min OA alone). 
Two-dimensional phosphopeptide maps of MLC from tracheal smooth muscle treated with carbachol (B) or carbachol plus okadaic acid (C). 
the protein phosphatase inhibitor okadaic acid (3 pM) 
relaxes precontracted tracheal smooth muscle with no 
significant decrease in the extent of MLC phosphoryla- 
tion, it is reasonable to postulate the existence of 
another biochemical mechanism that is regulating 
smooth muscle contraction. The maintenance of MLC 
phosphorylation is probably due to inhibition of the 
protein phosphatase that dephosphorylates this pro- 
tein. Relaxation could be mediated by the decrease in 
[Ca2+lcfi resulting in inhibition of phosphorylated 
myosin crossbridge interactions with actin, potentially 
mediated by thin filament regulatory proteins such as 
calponin or caldesmon [3,4,17]. The decrease in 
[Ca2+lcyl may be due to inhibition of a protein 
phosphatase that dephosphorylates proteins involved in 
Ca2+ influx. Alternatively, okadaic acid treatment 
could lead to phosphorylation of a contractile 
regulatory protein in addition to MLC. In either case, 
this raises the possibility that a phosphoprotein may be 
involved in the secondary regulation of smooth muscle 
relaxation. Our findings indicate that MLC 
phosphorylation is not the only mechanism involved in 
the regulation of tension maintenance in smooth 
muscle. 
Acknowledgemenls: The authors are thankful to Dr Daisuke Uemura 
for okadaic acid, to the Ministry of Education, Science and Culture 
of Japan for a Grant-in-Aid for Scientific Research (H.K.), and to 
NIH for grant support (K.E.K. and J.T.S.). 
REFERENCES 
[II 
121 
131 
141 
ti; 
171 
PI 
PI 
1101 
[III 
[121 
1131 
1141 
DSI 
t:y 
Kamm, K.E. and Stull, J.T. (1985) Annu. Rev. Pharmacol. 
Toxicol. 25, 593-620. 
Hai, C.-M. and Murphy, R.A. (1989) Annu. Rev. Physiol. 51, 
285-298. 
Marston, S.B. (1989) J. Muscle Res. Cell Motil. 10, 97-100. 
Takahashi, K., Hiwada, K. and Kokubu, T. (1988) 
Hypertension 11, 620-626. 
Takai, A. (1988) J. Muscle Res. Cell Motil. 9, 563-565. 
Shibata, S., Ishida, Y., Kitano, H., Ohizumi, Y., Habon, J., 
Tsukitani, Y. and Kikuchi, H. (1982) J. Pharmacol. Exp. Ther. 
233, 135-143. 
Ozaki, H., Kohama, K., Nonomura, Y., Shibata, S. and 
Karaki, H. (1987) Naunyn-Schmiedebergs Arch. Pharmacol. 
335, 356-358. 
Colburn, J.C., Michnoff, C.H., Hsu, L., Slaughter, C.A., 
Kamm, K.E. and Stull, J.T. (1988) J. Biol. Chem. 263, 
19166-19173. 
Sato, K., Ozaki, H. and Karaki, H. (1988) J. Pharmacol. Exp. 
Ther. 246, 294-300. 
Grynkiewicz, G., Poenie, M. and Tsien, R.Y. (1985) J. Biol. 
Chem. 260, 3440-3450. 
Persechini, A., Kamm, K.E. and Stull, J.T. (1986) J. Biol. 
Chem. 261, 6293-6299. 
Kamm, K.E., Hsu, L.-C., Kubota, Y. and Stull, J.T. (1989) J. 
Biol. Chem. 263, 19166-19173. 
Hartshorne, D.J. (1987) in: Physiology of the GI Tract 
(Johnson, L.R. ed.) Biochemistry of the Contractile Process in 
Smooth Muscle, vol. 2, pp. 423-482, Raven, New York, USA. 
Karaki, H. (1989) Trends Pharmacol. Sci. 10, 320-325. 
Kamm, K.E. and Stull, J.T. (1989) Annu. Rev. Physiol. 51, 
299-313. 
Gerthoffer, W.T. (1987) J. Pharmacol. Exp. Ther. 240, 8-15. 
Winder, S. J. and Walsh, M.P. (1990) J. Biol. Chem. 265, 
10148-10155. 
221 
